CoronaryAtlas logo
CoronaryAtlas
Osteopontin
Pathway / Plaque inflammation

Osteopontin

SPP1protein

Osteopontin promotes macrophage-fibroblast crosstalk and collagen remodeling, destabilizing the plaque and driving post-MI cardiac remodeling.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleMacrophage-driven inflammation and collagen deposition; plaque instability marker.
Also acts inCap degradation / rupture, Myocardial injury, Platelet activation
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000118785

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
61
C — confounder / Type-II
90
A — assay feasibility
72
E — evidence strength
33
T1DI (composite)
9
Specificity differential (R−C)-28.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.019
Open Targets association (STEMI)

Literature evidence(8)